Article

A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Toxicology and Applied Pharmacology (Impact Factor: 3.71). 12/2011; 258(2):268-74. DOI: 10.1016/j.taap.2011.11.006
Source: PubMed

ABSTRACT

Farnesoid X receptor (FXR) is a ligand-activated nuclear receptor and serves as a key regulator to maintain health of the liver and intestine. Bile acids are endogenous ligands of FXR, and there are increasing efforts to identify FXR modulators to serve as biological probes and/or pharmaceutical agents. Natural FXR ligands isolated from plants may serve as models to synthesize novel FXR modulators. In this study, we demonstrated that epigallocatechin-3-gallate (EGCG), a major tea catechin, specifically and dose-dependently activates FXR. In addition, EGCG induced FXR target gene expression in vitro. Surprisingly, in a co-activator (SRC2) recruitment assay, we found that EGCG does not recruit SRC2 to FXR, but it dose-dependently inhibits recruitment of SRC2 to FXR (IC(50), 1μM) by GW6064, which is a potent FXR synthetic ligand. In addition, EGCG suppressed FXR target gene expression induced by either GW4064 or chenodeoxycholic acid in vitro. Furthermore, wild-type and FXR knockout mice treated with an acute dose of EGCG had induced mRNA expression in a subset of FXR target genes in the intestine but not in the liver. In conclusion, EGCG is a unique modulator of FXR in the intestine and may serve as an important model for future development of FXR modulators.

Download full-text

Full-text

Available from: Grace Guo, Apr 25, 2014
  • Source
    • "Gene Expression Assays and GeneBLAzer Assays. Gene- BLAzer cells individually expressing the ligand-binding domains of farnesoid X receptor (FXR), glucocorticoid receptor (GR), liver X receptor (LXR) a, LXRb, peroxisome proliferator-activated receptor (PPAR) g, RXRa, RXRb, or vitamin D receptor (VDR) fused to the GAL4-DNA binding domain (GAL4-DBD) were obtained from Life Technologies (Li et al., 2012; Yu et al., 2013). On activation with the respective agonist, b-lactamase is expressed under the transcriptional control of an Upstream Activator Sequence, and a FRET-based substrate (CCF2-AM) is used to measure the enzyme activity of b-lactamase. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are xenobiotic sensors that enhance detoxification and elimination of xenobiotics and endobiotics by modulating the expression of genes encoding drug-metabolizing enzymes and transporters. Elevated levels of drug-metabolizing enzymes and efflux transporters, resulting from CAR activation in various cancers, promote the elimination of chemotherapeutic agents, leading to reduced therapeutic effectiveness and acquired drug resistance. CAR inhibitors in combination with existing chemotherapeutics could therefore be used to attenuate multidrug resistance in cancers. Interestingly, all previously reported CAR inverse-agonists are also activators of PXR, rendering them mechanistically counterproductive in tissues where both these xenobiotic receptors are present and active. We used a directed high-throughput screening approach, followed by subsequent mechanistic studies, to identify novel, potent, and specific small-molecule CAR inhibitors that do not activate PXR. We describe here one such inhibitor, CINPA1, capable of reducing CAR-mediated transcription with an IC50 of ~70 nM. CINPA1 (a) is a specific xenobiotic receptor inhibitor and has no cytotoxic effects up to 30 μM; (b) inhibits CAR-mediated gene expression in primary human hepatocytes, where CAR is endogenously expressed; (c) does not alter the protein levels or sub-cellular localization of CAR; (d) increases corepressor and reduces coactivator interaction with the CAR ligand-binding domain in mammalian two-hybrid assays; and (e) disrupts CAR binding to the promoter regions of target genes in chromatin immunoprecipitation assays. CINPA1 could be used as a novel molecular tool for understanding CAR function. The American Society for Pharmacology and Experimental Therapeutics.
    Full-text · Article · Mar 2015 · Molecular pharmacology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to assess the contents of indigo's bioactive compounds, its antioxidant and anticancer activities in acetone, hexane and DMSO extracts and to compare the overall bioactivity with another more used medicinal plant named prolipid. It was found that the contents of the bioactive compounds in the studied extracts from different parts of indigo plant varied (P < 0.05): the significantly highest content of polyphenols and flavonoids was in DMSO extract of prolipid, flavanols – in acetone extract of brown seeds (P < 0.05 in both cases) and tannins – in DMSO extract of green leaves, but not significantly (P > 0.05). Also the level of antioxidant activity was different: the highest antioxidant activity of all studied samples was in prolipid: according to ABTS, FRAP and CUPRAC tests in DMSO extract (P < 0.05 in all 3 cases), and only in acetone extract according to DPPH was not significant (P > 0.05). The correlations between polyphenol compounds and the antioxidant activities were relatively high. DPPH kinetic measurements were used to compare and distinguish the antiradical activity among indigo extracts by multivariate analysis. The FT-IR spectroscopy evaluated the presence of polyphenols. The interaction between DMSO polyphenol extracts of indigo plant and BSA showed that indigo has a strong ability as other medicinal plants such as prolipid to quench the intrinsic fluorescence of BSA by forming complexes and was measured by 3-dimensional fluorescence (3D-FL). The highest anticancer activity was in prolipid in concentrations of 800 μg/mL against Calu-6, following by indigo brown leaves. In conclusion, organic extracts of indigo brown leaves were analyzed for their antioxidant and anticancer activities and compared with prolipid, using polyphenols composition, antioxidant activities and fluorescence properties. The indigo ability to quench the intrinsic fluorescence of BSA, relatively high content of phenolic compounds and anticancer properties can be used as medicinal plant.
    Full-text · Article · Mar 2013 · Industrial Crops and Products
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the study: Diets containing high cholesterol levels led to atherosclerosis damage in the livers and hearts of rats. The aim of this study was to investigate the possible positive effects of durian fruit against high-cholesterol diets. Materials and methods: Durians at various stages of ripening (young, mature, ripe and overripe) were chosen for in vitro and in vivo studies. In the in vivo study 36 male Wistar rats were divided into 6 groups and supplemented with cholesterol and durians. The bioactivity in vitro, plasma lipids, antioxidant activity, liver enzymes and histopathology of the aorta and liver were analyzed. Results: Polyphenols and flavonoids were significantly higher in the overripe durian, while quercetin, ascorbic acid and anthocyanins were more abundant in the ripe fruit and tannins - in mature samples (P<0.05). The highest antioxidant potential was in overripe fruit and only the value of FRAP - in ripe durian samples (P<0.05). The interaction between polyphenol extracts of ripe durian and BSA had a strong ability comparable to that of quercetin - to quench the intrinsic fluorescence of BSA by forming complexes. The main histopathological changes were detected in the liver and aorta of rats fed a high-cholesterol diet without fruit supplementation. These changes were minor in rats of Chol/DRipe (P<0.05). Conclusion: Durian at different stages of ripening, especially ripe durian, constitute an excellent source of effective natural compounds with antioxidant and health-protective activity in general and liver and heart-protective effect in cholesterol fed rats in particular.
    Full-text · Article · Sep 2011 · European Journal of Integrative Medicine
Show more